References

  1. George MS, et al. (2010). Daily Left Prefrontal Transcranial Magnetic Stimulation Therapy for Major Depressive Disorder: A Sham-Controlled Randomized Trial. Arch Gen Psychiatry, 67(5):507-516.
  2. Sackeim HA, et al. (2020). Clinical Outcomes in a Large Registry of Patients with Major Depressive Disorder Treated with Transcranial Magnetic Stimulation. J Affective Disorders, 277(12):65-74.
  3. Carpenter, LL, et al. (2021). Comparison of Clinical Outcomes with Two Transcranial Magnetic Stimulation Treatment Protocols for Major Depressive Disorder. Brain Stim, 14(1): 173-180.
  4. Data on file. Neuronetics, Inc.
  5. https://factfinder.census.gov/faces/nav/jsf/pages/index.xhtml, accessed 1/16/2018.
  6. Kessler RC, et al. (2005). Arch Gen Psychiatry, 62(6): 593-602.
  7. Gaynes BN, et al. (2008). Cleveland Clinic J of Medicine. 75(1):57-66.
  8. https://www.who.int/news-room/fact-sheets/detail/depression.
  9. https://www.nimh.nih.gov/health/statistics/major-depression.shtml, accessed 1/4/2020.
  10. Per STAR*D patients that have failed one or more antidepressant trial of adequate dose and duration.
  11. Trivedi MH, et al. (2006). Evaluation of Outcomes with Citalopram for Depression Using Measurement-Based Care in STAR*D Implications for Clinical Practice. Am J Psychiatry, 163(1):28-40.
  12. Rush AJ, et al. (2006). Acute and Longer-Term Outcomes in Depressed Outpatients Requiring One or Several Treatment Steps: A STAR*D Report. Am J Psychiatry, 163:1905–1917.
  13. Fava M, et al. (2006). A Comparison of Mirtazapine and Nortriptyline Following Two Consecutive Failed Medication Treatments for Depressed Outpatients: A Star*D Report. Am J Psychiatry, 163(7):1161-1172.
  14. McGrath PJ, et al. (2006). Tranylcypromine Versus Venlafaxine Plus Mirtazapine Following Three Failed Antidepressant Medication Trials for Depression: A STAR*D Report. Am J Psychiatry, 163(9):1531-1541.
  15. O’Reardon JP, et al. (2007). Efficacy and Safety of Transcranial Magnetic Stimulation in the Acute Treatment of Major Depression: A Multisite Randomized Controlled Trial. Biol Psychiatry, 62(11):1208-1216.
  16. McDonald WM, et al. (2011). Improving the Antidepressant Efficacy of Transcranial Magnetic Stimulation: Maximizing the Number of Stimulations and Treatment Locations in Treatment-Resistant Depression. Depress Anxiety, 28:973-980.
  17. Janicak PG, et al. (2008). Transcranial Magnetic Stimulation in the Treatment of Major Depressive Disorder: A Comprehensive Summary of Safety Experience from Acute Exposure, Extended Exposure, and During Reintroduction Treatment. J Clin Psychiatry, 69(2):222-232.
  18. Liston C, et al. (2014). Default Mode Network Mechanisms of Transcranial Magnetic Stimulation in Depression. Biol Psychiatry, 76(7): 517–526.
  19. Deng ZD, et al. (2013). Electric Field Depth-Focality Tradeoff in Transcranial Magnetic Stimulation: Stimulation Comparison of 50 Coil Designs. Brain Stimuli, 6(1):1-13.
  20. Dunner DL, et al. (2014) A Multisite, Naturalistic, Observational Study of Transcranial Magnetic Stimulation (TMS) for Patients with Pharmacoresistant Major Depression: Durability of Benefit Over a One-Year Follow-Up Period. J Clin Psych, 75(12):1394-1401.
  21. Carpenter LL, et al. (2012). Transcranial Magnetic Stimulation (TMS) for Major Depression: A Multisite Naturalistic, Observational Study of Acute Treatment Outcomes in Clinical Practice. Depress Anxiety, 29(7):587-596.
  22. Avery, et al. (2008). Transcranial Magnetic Stimulation in the Acute Treatment of Major Depressive Disorder: Clinical Response in an Open-Label Extension Trial. J Clin Psychiatry, 69(3):441-451.
  23. Janicak PG, et al. (2010). Durability of Clinical Benefit with Transcranial Magnetic Stimulation (TMS) in the Treatment of Pharmacoresistant Major Depression: Assessment of Relapse During a 6-Month, Multisite, Open-Label Study. Brain Stimulation, 3(4):187-199.
  24. Mantovani A, et al. (2012). Long-Term Efficacy of Repeated Daily Prefrontal Transcranial Magnetic Stimulation (TMS) in Treatment-Resistant Depression. Depress Anxiety, 29 (10):883-890.
  25. 2013 CPT Current Procedural Terminology Professional Edition, American Medical Association.
  26. Regulation No.: CMS-1678-FC Federal Register/Vol. 82, No. 239, Thursday, December 14, 2017/Rules and Regulations.
  27. Post A, et al. (2001). J Psychiatric Research, 35:193-215 6.
  28. Liston C, et al.(2014). Biol Psychiatry, 76(7):517-26.
  29. NeuroStar Prescribing Information.